Last reviewed · How we verify
Pletal
At a glance
| Generic name | Pletal |
|---|---|
| Sponsor | Otsuka America Pharmaceutical |
| Target | Cytochrome P450 2C9, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited 3',5'-cyclic phosphodiesterase B |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Intermittent claudication
Common side effects
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage (PHASE2)
- The Effect of Cilostazol on Rheumatoid Arthritis Patients (PHASE2, PHASE3)
- Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial (PHASE1)
- Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage (PHASE3)
- Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (PHASE1, PHASE2)
- Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pletal CI brief — competitive landscape report
- Pletal updates RSS · CI watch RSS
- Otsuka America Pharmaceutical portfolio CI